Market Place
Sourcing Support
Novartis` Arzerra (ofatumumab) Receives Suppl Approval in the U.S.
12 Apr 2024 //
FDA
Novartis` Kesimpta (ofatumumab) Receives Suppl Approval in the U.S.
12 Apr 2024 //
FDA
Novartis presents new five-year data disability outcomes and safety of Kesimpta
20 Apr 2023 //
GLOBENEWSWIRE
Novartis presents new 5-year data on disability outcomes and safety of Kesimpta
19 Apr 2023 //
PR NEWSWIRE
Novartis` Kesimpta Receives Approval in Europe
08 Dec 2022 //
EMA
Novaris`s Biologic Arzerra (Ofatumumab) Receives Approval in the U.S.
02 Sep 2022 //
FDA
Kesimpta surges as Kisqali starts to ramp at Novartis
19 Jul 2022 //
FIERCEPHARMA
FDA Warns of Increased Mortality Risk With Duvelisib
01 Jul 2022 //
MEDPAGETODAY
Continuous treatment with Kesimpta sees RMS patients achieving NEDA-3
30 Jun 2022 //
EUROPEANPHARMACEUTICALREVIEW
Tecentriq, Kesimpta lead latest SMC decisions
13 Jul 2021 //
PHARMATIMES
Kesimpta (ofatumumab) data show long-term preservation of IgG/IgM levels
22 Jun 2021 //
PRESS RELEASE
Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression
16 Apr 2021 //
PRESS RELEASE
Novartis MS therapy gains MHRA and EC approval
09 Apr 2021 //
PHARMAFILE
Novartis bags EU, UK licences for MS therapy Kesimpta
07 Apr 2021 //
PHARMATIMES
EC approves Novartis’s Kesimpta for relapsing multiple sclerosis
31 Mar 2021 //
PHARMACEUTICAL-TECHNOLOGY
Novartis says Kesimpta gets EU approval in multiple sclerosis
30 Mar 2021 //
PRESS RELEASE
Novartis receives EU approval for Kesimpta® (ofatumumab), the first
29 Mar 2021 //
PRESS RELEASE
Novartis launches first TV ads for MS med Kesimpta
24 Feb 2021 //
FIERCE PHARMA
Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab)
29 Jan 2021 //
PRESS RELEASE
Facing Novartis rival, Roche`s Ocrevus wins OK for easier dosing
16 Dec 2020 //
FIERCE PHARMA
Novartis MS Drug Kesimpta Quick Out Of The Blocks
15 Dec 2020 //
PHARMAINTELLIGENCE
Novartis`s Arzerra (Ofatumumab) Receives Supplemental Approval in US
22 Aug 2020 //
FDA
Novartis`s Kesimpta (Ofatumumab) Receives Supplemental Approval in US
22 Aug 2020 //
FDA
FDA approves Novartis Kesimpta®, the first and only self-administered
20 Aug 2020 //
PRESS RELEASE
Novartis builds its case for novel MS treatment ofatumumab
06 Aug 2020 //
PMLIVE
U.S. FDA extends review of Novartis` multiple sclerosis drug
04 Jun 2020 //
REUTERS
U.S. FDA extends review of Novartis` multiple sclerosis drug
03 Jun 2020 //
REUTERS
Novartis` leukemia drug tops Sanofi`s Aubagio in MS study
28 May 2020 //
FIERCE PHARMA
Novartis announces new late-breaking ofatumumab data at EAN
26 May 2020 //
GLOBENEWSWIRE
Roche`s Ocrevus Continues to Impress in the EU with Strong Uptake
08 Apr 2020 //
PR NEWSWIRE
EMA, FDA both accept filing of Novartis’ ofatumumab
25 Feb 2020 //
PHARMA TIMES
Celgene’s Phase III study for myeloid leukaemia meets endpoints
16 Sep 2019 //
CLINICALTRIALSARENA
Novartis` reinvented leukemia drug bests Sanofi`s Aubagio in MS
14 Sep 2019 //
FIERCE PHARMA
Novartis MS drug cuts relapse rate by half compared to Sanofi medicine
13 Sep 2019 //
REUTERS
J&J`s head-to-head PhIII data promise drug launch into crowded MS market
13 Sep 2019 //
ENDPOINTSNEWS
Novartis reports positive Phase III data for multiple sclerosis drug
03 Sep 2019 //
CLINICALTRIALSARENA
Novartis` repurposed cancer drug Arzerra outpaces Sanofi`s Aubagio in MS trial
31 Aug 2019 //
FIERCE PHARMA
Novartis jumps on ofatumumab MS data
30 Aug 2019 //
THE PHARMALETTER
Genmab Raises $506 Million in IPO
19 Jul 2019 //
BIOSPACE
Novartis CEO Vas Narasimhan lines up his late-stage blockbuster contenders
06 Nov 2018 //
ENDPTS
Genmab/Novatis’ Arzerra fails to hit NHL targets
26 May 2018 //
PHARMA TIMES
Under-pressure Novartis pulls Arzerra outside the U.S.
23 Jan 2018 //
FIERCE PHARMA
Verastem’s AbbVie castoff is headed for the FDA even after missing survival goal
12 Dec 2017 //
ENDPTS
Novartis highlights differentiated late stage pipeline at R&D
13 Nov 2017 //
PHARMABIZ
EU Commission Grants Marketing Authorization for Arzerra
12 Dec 2016 //
GLOBENEWSWIRE
Novartis in Talks to Sell Some Central Nervous System Drugs
07 Dec 2016 //
REUTERS
Novartis stops PhIII trial of Genmab`s Arzerra after buying rights from GSK
11 Mar 2016 //
FIERCE BIOTECH
Genmab`s lymphoma project flops in Phase III with Novartis holding the bag
24 Nov 2015 //
FIERCE BIOTECH
Genmab`s Arzerra gets six-month for maintenance CLL
21 Sep 2015 //
PHARMATIMES
GSK to Divest Ofatumumab to Novartis Pharma
28 Aug 2015 //
PHARMEXEC
Novartis buys remaining rights to GSK treatment for up to $1 billion
21 Aug 2015 //
REUTERS
GSK deal keeps paying off for Novartis with more positive Arzerra data
13 Jun 2015 //
FIERCE PHARMA MANUFACTURING
Novartis` Arzerra Shows Benefit in Relapsed CLL
27 Apr 2015 //
PHARMATIMES
QALY Denying Access to Cancer Drugs: Study
26 Jan 2015 //
PHARMATIMES DIGITAL
